References
- Abbott, R. B., Bader, R., Bajjali, L., ElSamen, T. A., Obeidat, T., Sboul, H., … Alabbadi, I. (2012). The price of medicines in Jordan: The cost of trade-based intellectual property. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector, 9(2), 75–85. doi: 10.1177/1741134312447499
- Akaleephan, C., Wibulpolprasert, S., Sakulbumrungsil, R., Luangruangrong, P., Jitraknathee, A., Aeksaengsri, A., … Tantivess, S. (2009). Extension of market exclusivity and its impact on the accessibility to essential medicines, and drug expense in Thailand: Analysis of the effect of TRIPs-plus proposal. Health Policy, 91, 174–182. doi: 10.1016/j.healthpol.2008.12.009
- Arup, C. J., & Plahe, J. (2016). Access to medicines in the mature TRIPS regime: A sceptical view. Retrieved from SSRN http://ssrn.com/abstract=2730395
- Baker, B. K. (2013). US’s proposed TPP transition period for middle-income parties is Fools Gold. Retrieved from http://infojustice.org/archives/31540
- Baker, B. K. (2016). Trans-Pacific Partnership provisions in intellectual property, transparency and investment chapters threaten access to medicines in the US and elsewhere. PLOS Medicine, 13(3), e1001970. doi: 10.1371/journal.pmed.1001970
- Bhardwaj, K., & Oh, C. (2014). The Trans-Pacific Partnership agreement: Implications for access to medicines and public health. UNITAID, WHO.
- Chan, M. (2014, May 19). Health has an obligatory place in any post-2015 agenda. Address to the Sixty-seventh World Health Assembly, Geneva.
- Drahos, P. (2008). “Trust me”: Patent offices in developing countries. American Journal of Law & Medicine, 34, 151–174. doi: 10.1177/009885880803400205
- Duong, A. T., Kato, M., Bales, S., Do, N. T., Minh Nguyen, T. T., Thanh Cao, T. T., & Nguyen, L. T. (2014). Costing analysis of national HIV treatment and care program in Vietnam. JAIDS Journal of Acquired Immune Deficiency Syndromes, 65(1), e1–e7. doi: 10.1097/QAI.0b013e3182a17d15
- Godoy, A. S., & Cerón, A. (2011). Changing drug markets under new intellectual property regimes: The view from Central America. American Journal of Public Health, 101(7), 1186–1191. doi: 10.2105/AJPH.2010.300071
- Government of Vietnam. (2012). Annual report of the HIV prevention and control program 2013 and plan for 2014. Ministry of Health.
- Government of Vietnam. (2013). Prime Minister’s decision on approval of the project on sustainable financing for HIV/AIDS prevention and control activities in 2013-2020 period. Hanoi, Vietnam.
- Harris, T., Nicol, D., & Gruen, N. (2013). Pharmaceutical patents review report. Canberra. Retrieved from http://www.ipaustralia.gov.au/pdfs/2013-05-27_PPR_Final_Report.pdf
- Hemphill, C. S., & Sampat, B. N. (2012). Evergreening, patent challenges, and effective market life in pharmaceuticals. Journal of Health Economics, 31, 327–339. doi: 10.1016/j.jhealeco.2012.01.004
- IFARMA and Fundacion Mision Salud. (2009a). Impact of the EU-Andean trade agreement on access to medicines in Colombia.
- IFARMA and Fundacion Mision Salud. (2009b). Impact of the EU-Andean trade agreement on access to medicines in Peru.
- Inside U.S. Trade. (2013, November 27). In TPP, U.S. floats 12-year data period for biologics, flexibilities for developing countries. Posted.
- Kessomboon, N., Limpananont, J., Kulsomboon, V., Maleewong, U., Eksaengsri, A., & Paothong, P. (2010). Impact on access to medicines from TRIPS-plus: A case study of Thai-US FTA. Southeast Asian Journal of Tropical Medicine and Public Health, 41(3), 667–677.
- Kiliç, B., & Maybarduk, P. (2011, June). Comparative analysis of the United States’ TPFTA intellectual property proposal and Vietnamese Law. Public Citizen (updated December 2011). Retrieved from www.citizen.org/access
- Labonté, R., Schram, A., & Ruckert, A. (2016). The Trans-Pacific Partnership: Is it everything we feared for health? International Journal of Health Policy and Management, 5(8), 487–496. doi: 10.15171/ijhpm.2016.41
- Lexchin, J., & Gagnon, M.-A. (2014). CETA and pharmaceuticals: Impact of the trade agreement between Europe and Canada on the costs of prescription drugs. Globalization and Health, 10, 30. doi:10.1186/1744-8603-10-30.
- Lopert, R., & Gleeson, D. (2013). The high price of “free” trade: U.S. Trade agreements and access to medicines. Global Health and the Law, 41(1), 199–223.
- Médecins Sans Frontières. (2013a). Untangling the web of antiretroviral price reductions (16th ed.). Retrieved from http://www.msfaccess.org/sites/default/files/AIDS_Report_UTW16_ENG_2013.pdf
- Médecins Sans Frontières. (2013b). As Trans-Pacific trade talks accelerate, vital lifeline of affordable medicines under threat. Retrieved from http://msfaccess.org/sites/default/files/MSF_UTW_17th_Edition_4_b.pdf
- Ministry of Health. (2009). National guidelines for HIV/AIDS diagnosis and treatment. Retrieved from https://aidsfree.usaid.gov/sites/default/files/hts_policy_vietnam.pdf.
- Moir, H. V. J. (2013). Fabricating invention: The patent malfunction of Australian patent law. Agenda, 20(2), 21–38.
- Moir, H. V. J., & Palombi, L. (2013). Patents and trademarks: empirical evidence on ‘evergreening’ from Australia. Paper presented at 4th Asia-Pacific Innovation conference, National Taiwan University, Taipei. Retrieved from http://ssrn.com/abstract=2365786
- Moir, H. V. J., Tenni, B., Gleeson, D. H., & Lopert, R. (2014). Assessing the impact of alternative patent systems on the cost of health care: the TPPA and HIV treatment in Vietnam. Paper presented at 5th Asia-Pacific Innovation conference, University of Technology, Sydney. Retrieved from http://ssrn.com/abstract=2536254
- National Committee for AIDS, Drugs, Prostitution Prevention and Control. (2014). Vietnam AIDS response progress report. Following up the 2011 political declaration on HIV AIDS. Reporting period January 2012–December 2013. Hanoi.
- Nguyen, A. T., Knight, R., Mant, A., Cao, Q. M., & Brooks, G. (2010). Medicine pricing policies: Lessons from Vietnam. Southern Med Review, 3(2), 12–19.
- Nguyen, A. T. (2011). Medicine prices and priccing policies in Vietnam (PhD thesis). Faculty of medicine, University of New South Wales.
- Nguyen, N. L., Nguyen, T. H., & Hua, T. (2015). Evolving trade policy and the Trans-Pacific Partnership Agreement: Does it threaten Vietnam’s access to medicine and its progress towards scaling up HIV prevention, treatment and care? Global Public Health, 10(1), S149–S160.
- Oxfam International. (2007). All costs, no benefits: How TRIPS-plus intellectual property rules in the US-Jordan FTA affect access to medicines.
- Shaffer, E. R., & Brenner, J. E. (2009). A trade agreement’s impact on access to generic drugs. Health Affairs, 28(5), w957–w968. doi: 10.1377/hlthaff.28.5.w957
- UNAIDS. (2013). Viet Nam: South-South learning helps prepare for sustainable provision of AIDS treatment. Retrieved May 3, 2016, from http://www.unaids.org/en/resources/presscentre/featurestories/2013/may/20130516vietnam
- United States Secretary of State. (2015). Vietnam country operational plan 2015 – Strategic direction summary.
- US Trade Representative. (2013). Stakeholder input sharpens, focuses U.S. work on pharmaceutical intellectual property rights in the Trans-Pacific Partnership (Media Release). Retrieved August 4, 2014, from http://www.ustr.gov/about-us/press-office/blog/2013/November/stakeholder-input-sharpens-focuses-us-work-on-pharmaceutical-IP-in-TPP